Arvinas, Inc. (ARVN) came out with a quarterly loss of $2.53 per share versus the Zacks Consensus Estimate of a loss of $1.33. This compares to loss of $1.56 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -90.23%. A quarter ago, it was expected that this company would post a loss of $1.52 per share when it actually produced a loss of $1.18, delivering a surprise of 22.37%.Over the last four quarters, the company has surpassed ...

– Enrollment continues globally in multiple clinical studies of vepdegestrant (ARV-471) in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting and the study lead-in for the VERITAC-3 Phase 3 trial in the first-line setting – – Pending further data and discussions with regulatory authorities, the expanded development plan for vepdegestrant will include a new Phase 3 trial in combination with CDK4/6 inhibitors in the second-line setting and a new Phase 3 trial ...

Exhibit 99.1 Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update – Enrollment continues globally in multiple clinical studies of vepdegestrant (ARV-471) in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting and the study leadin for the VERITAC-3 Phase 3 trial in the first-line setting – – Pending further data and discussions with regulatory authorities, the expanded development plan for vepdegestrant will include ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________________________ FORM 10-K ________________________________________________ (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO . Commission File Number: 001-38672 (State or other No.) 5 Sci ...

Shares of Arvinas, Inc. (ARVN) have gained 23.1% over the past four weeks to close the last trading session at $46.51, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $60.56 indicates a potential upside of 30.2%.The average comprises 16 short-term price targets ranging from a low of $20 to a high of $95, with a standard deviation of $22.41. While the lowest estimate indicates a ...

Core Viewpoint - Momentum investing focuses on following a stock's recent price trends, with the aim of buying high and selling higher, leveraging established price movements for profitable trades [1] Company Overview: Arvinas, Inc. (ARVN) - Arvinas, Inc. currently holds a Momentum Style Score of A, indicating strong momentum characteristics [1] - The company has a Zacks Rank of 2 (Buy), suggesting it is positioned for potential outperformance in the market [2] Price Performance - Over the past week, ARVN shares increased by 4.85%, outperforming the Zacks Medical - Biomedical and Genetics industry, which rose by 0.51% [3] - In a longer timeframe, ARVN's monthly price change is 39.09%, significantly higher than the industry's 1.29% [3] - Over the past quarter, ARVN shares have surged by 107.21%, and they have gained 52.36% over the last year, while the S&P 500 only increased by 9.79% and 23.69%, respectively [4] Trading Volume - The average 20-day trading volume for ARVN is 751,814 shares, which serves as a bullish indicator when combined with rising stock prices [4] Earnings Outlook - In the past two months, one earnings estimate for ARVN has been revised upwards, while one has been revised downwards, leading to a consensus estimate increase from -$5.23 to -$5.18 [5] - For the next fiscal year, two estimates have moved upwards with no downward revisions during the same period [5] Conclusion - Given the strong momentum indicators and positive earnings outlook, ARVN is positioned as a 2 (Buy) stock with a Momentum Score of A, making it a potential candidate for investors seeking short-term gains [6]

BOSTON, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies, today announced that the first patient has been dosed in its Phase 1b/2 clinical trial evaluating the combination of samuraciclib (CT7001), an investigational oral and first-in-class inhibitor of CDK7, and vepdegestrant (ARV-471), an investigational oral PROTAC® (PROteolysis TArgeting Chimera) estrogen receptor (ER) degrader, being jointly ...

Shares of Arvinas, Inc. (ARVN) have gained 13.2% over the past four weeks to close the last trading session at $46.30, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $58.65 indicates a potential upside of 26.7%.The mean estimate comprises 17 short-term price targets with a standard deviation of $23.32. While the lowest estimate of $20 indicates a 56.8% decline from the current ...

-- Vepdegestrant is an investigational PROteolysis Targeting Chimera (PROTAC®) protein degrader designed to target and degrade the estrogen receptor (ER) protein -- NEW HAVEN, Conn. and NEW YORK, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN) and Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the investigation of vepdegestrant (ARV-471) for monotherapy in the treatment of adults with estrogen receptor (ER) positiv ...

Company Overview - Arvinas, Inc. (ARVN) shares increased by 10% to close at $45.65, with trading volume significantly higher than usual [1] - The stock's performance over the past four weeks showed a modest gain of 0.7% [1] Pipeline Progress - The surge in stock price is linked to positive investor sentiment regarding Arvinas' clinical pipeline, particularly the lead candidate vepdegestrant [1] - Vepdegestrant is being evaluated in two late-stage studies: VERITAC-2 and VERITAC-3, targeting second-line breast cancer as a monotherapy and in combination with Pfizer's Ibrance [1] - Arvinas also has two mid-stage candidates in development for prostate cancer [1] Financial Expectations - The company is projected to report a quarterly loss of $1.28 per share, reflecting an 18% year-over-year increase in losses [2] - Expected revenues for the upcoming quarter are $44.63 million, which is a 17.5% increase compared to the same quarter last year [2] - The consensus EPS estimate has been revised down by 6.6% over the last 30 days, indicating a negative trend in earnings estimate revisions [2] Industry Context - Arvinas is classified under the Zacks Medical - Biomedical and Genetics industry, which includes other companies like Prothena (PRTA) [3] - Prothena's stock closed 3.6% lower at $27.37, with a significant decline of 25.4% over the past month [3] - Prothena's consensus EPS estimate remains unchanged at -$1.07, representing a drastic change of -991.7% from the previous year [3]